new england journal of medicine retatrutide (not yet approved in US but people using anyway) promises even potentially greater weight loss amongst the GLP1 drugs. https://www.nejm .org/doi/full/10.1056/NEJMoa2301972 Retatrutide vs. Tirzepatide | Best

By activating GLP-1Rs on glial cells, these agents suppress pro-inflammatory cytokines (IL-1, TNF-) and block NF-B-mediated inflammatory cascades [10,24]

For patients who prefer oral medications over injections: Oral Wegovy (available January 2026) is the first FDA-approved oral GLP-1 for weight loss

doi: 10.1016/j.neuron.2019.02.028

The visits are virtual, convenient, and usually take about 10 minutes from my phone

A key mechanism involves acting on appetite centres in the hypothalamus, directly suppressing hunger signals and reducing food cravings

HW TIPS TO MINIMIZE GI SIDE EFFECTS One or more gastrointestinal (GI) side effects are observed in roughly 10% to 50% of people who take one of these weight management medications.1,2 From nausea and vomiting to acid reflux, bloating, stomach cramps, diarrhea, and/or constipation, patients can minimize GI side effects with a start low, go slow approach, starting with the lowest dose and titrating as recommended (see table Currently FDA-Approved Mono and Dual Agonists)